Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Pilot series of Southeast Asian eyes which underwent combined iStent trabecular micro-bypass device implantation and cataract surgery

Poster Details

First Author: C.Sng SINGAPORE

Co Author(s):    S. Loon   P. Chew                 

Abstract Details

Purpose:

Analysis of single-surgeon outcomes following combined iStent trabecular micro-bypass device (iStent, Glaukos Corp., USA) implantation with cataract surgery.

Setting:

National University Hospital, a tertiary care centre in Singapore

Methods:

We included 30 eyes of 25 patients who underwent iStent implantation with cataract surgery. Twelve eyes were diagnosed with primary open angle glaucoma (POAG) and 18 eyes were diagnosed with primary angle closure glaucoma (PACG). A single iStent was implanted in 7 eyes while two iStents were implanted in 23 eyes. Post-operatively, patients were assessed on days 1 and 7, and months 1, 3 and 6. The intraocular pressure (IOP), glaucoma medication use and complications were assessed at each visit.

Results:

The mean pre-operative IOP was 16.7�Â�±3.6 mmHg with 1.2�Â�±0.5 glaucoma medications and 23.9�Â�±2.5 mmHg without medications. At 6 months after the surgery, there was a significant decrease in the mean number of glaucoma medications (0.03�Â�±0.18, p<0.001) and the mean IOP compared to the pre-operative medicated and unmedicated IOP (14.9�Â�±2.6 mmHg, p=0.01 and p<0.001 respectively). There was no significant difference in pre-operative and post-operative IOP and glaucoma medications between POAG and PACG eyes, and between eyes implanted with one and two iStents. Two eyes had post-operative hyphaema which resolved by 1 week after the surgery and there were no other complications.

Conclusions:

Outcomes from this pilot series of South East Asian eyes that underwent combined iStent implantation with cataract surgery suggest that meaningful IOP and medication reductions can be achieved for at least 6 months, with a favorable safety profile.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to Poster listing